Financial results for the period ended September 30, 2026
As filed · Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
What happened
FactFinancial results for the period ended September 30, 2026. (1) Approval of Unaudited Financial Results for the quarter and half-year ended September 30, 2026. Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedWe see significant jump in our animal health revenues in FY26.
Non-ARV formulation revenue will go up from Q3 onwards.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Majority of FY'27 revenues in our CDMO division will be commercial supplies and I think that much I can make a (management committed by FY27)
- We expect a good growth in CDMO segment. (management committed by FY27)
Evidence
- Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q4 FY25
- Earlier statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%